Parr Mcknight Wealth Management Group LLC Acquires 1,702 Shares of Eli Lilly and Company $LLY

Parr Mcknight Wealth Management Group LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 27.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,918 shares of the company’s stock after purchasing an additional 1,702 shares during the quarter. Eli Lilly and Company comprises about 1.1% of Parr Mcknight Wealth Management Group LLC’s portfolio, making the stock its 18th biggest position. Parr Mcknight Wealth Management Group LLC’s holdings in Eli Lilly and Company were worth $9,497,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $30,000. Maseco LLP increased its stake in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. lifted its position in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after acquiring an additional 27 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 3.7%

Eli Lilly and Company stock opened at $1,227.11 on Wednesday. Eli Lilly and Company has a 1-year low of $685.15 and a 1-year high of $1,249.45. The firm has a market capitalization of $1.16 trillion, a price-to-earnings ratio of 41.18, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. The firm’s fifty day moving average price is $1,173.20 and its two-hundred day moving average price is $1,055.15. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 23.22%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on LLY shares. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Royal Bank Of Canada raised their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Sanford C. Bernstein upped their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Finally, Bank of America increased their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,292.18.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Weight-loss leadership remains a key catalyst. Eli Lilly was highlighted as an IBD Stock of the Day as its obesity-drug business gains ground on Novo Nordisk. Investor attention is also focused on the company’s next-generation obesity candidate retatrutide following encouraging trial-related developments. Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills
• Positive Sentiment: Recent quarterly results support the bullish outlook. Lilly’s latest reported quarter substantially exceeded earnings and revenue expectations, with revenue up 47.7% year over year. Analysts cited GLP-1 momentum, a broad pipeline and strong operating growth as reasons for continued long-term momentum. LLY Up Around 6% Post Robust Q2 Results
• Positive Sentiment: Pipeline expansion continued through partnerships. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program, potentially providing access to new medicines. It also made a $10 million upfront payment to AlzeCure for rights connected to small-molecule CNS treatments, including Alzheimer’s and pain candidates. OmniAb Enters Collaboration and License Agreement with Eli Lilly
• Neutral Sentiment: International execution is progressing. Lilly appointed Tayllit Aherdan to lead operations in the United Arab Emirates, Qatar and Kuwait, supporting its commercial expansion in the Middle East. Lilly Appoints Tayllit Aherdan
• Negative Sentiment: Valuation and competition remain risks. Analysts noted that Lilly’s premium valuation leaves less room for execution misses, while competition, pricing pressure and future obesity-drug rivals could moderate upside.
• Negative Sentiment: An executive sale adds a minor sentiment headwind. EVP Patrik Jonsson sold 6,500 shares worth approximately $7.6 million. However, the transaction was made under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal. SEC Insider Transaction Filing

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.